TY  - JOUR
T1  - Cardiovascular Protection of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Type 2 Diabetes Mellitus; Literature Review
A1  - Ziyad Ali Alsaedi
A1  - Khalid Mohammed Alahmadi
A1  - Abdulaziz Zakaria Khan
A1  - Ezzaddin Mugahed Alrait
A1  - Mohammed Khaled Al Ghamdi
A1  - Abdullah Mutrik Alqahtani
A1  - Hadil Ali Alkahmous
A1  - Rakan Saleh Alanazi
A1  - Anas Abdulrhman Aljohani
A1  - Wessam Ahmed Alsawyan
A1  - Faisal Ayed Almazariqi
A1  - Abdullah oudah saeed al jabal
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2021
VL  - 10
IS  - 2
DO  - 10.51847/acxDC9hQpC
SP  - 139
EP  - 143
N2  - Diabetes mellitus is a significant risk factor for major adverse cardiovascular events and all-cause mortality. It is essential to control blood glucose levels, but a combination of controlled blood glucose and cardioprotective effect, mortality, and morbidity secondary to diabetes would be significantly reduced. Sodium-glucose co-Transporter 2 inhibitor provides great diabetic control in addition to protection against cardiovascular events, with or without increased cardiovascular risks. This narrative review aims to assess the efficacy and safety of SGLT2i in preventing cardiovascular consequences among patients with diabetes mellitus type-2. A search in the PubMed database was performed for relevant articles using the following Mesh words: Sodium-glucose co-transporter 2 inhibitor, an SGLT2 inhibitor, Cardiovascular protection, Cardiovascular events, myocardial infarction. SGLT-2 inhibitors were found to provide cardiovascular protection and decreased all-cause of death in addition to reasonable glycemic control compared to placebo. Several rare adverse effects were reported, but generally, all of them were affordable and well-tolerated. Further trials are recommended to establish SGLT-2 inhibitors concerning the risk of amputations. 
UR  - https://ijpras.com/article/cardiovascular-protection-of-sodium-glucose-co-transporter-2-inhibitors-sglt2i-in-type-2-diabetes-b5wx0v5qdncuood
ER  -